John J Bissler

List of Publications by Year in descending order

114 papers	8,529 citations	87888 38 h-index	45317 90 g-index
115 all docs	115 docs citations	115 times ranked	6986 citing authors

#	Article	IF	Citations
1	Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology, 2013, 49, 243-254.	2.1	1,185
2	Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis. New England Journal of Medicine, 2008, 358, 140-151.	27.0	1,138
3	Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet, The, 2013, 381, 817-824.	13.7	712
4	Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology, 2013, 49, 255-265.	2.1	693
5	Renal angiomyolipomata. Kidney International, 2004, 66, 924-934.	5.2	266
6	Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 748-761.	5.6	236
7	Characterization of Fabry Disease in 352 Pediatric Patients in the Fabry Registry. Pediatric Research, 2008, 64, 550-555.	2.3	235
8	Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatric Neurology, 2021, 123, 50-66.	2.1	230
9	Serum Vascular Endothelial Growth Factor-D Prospectively Distinguishes Lymphangioleiomyomatosis From Other Diseases. Chest, 2010, 138, 674-681.	0.8	188
10	Identification of 54 large deletions/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations. Human Genetics, 2007, 121, 389-400.	3.8	162
11	Tuberous Sclerosis Complex: Renal Imaging Findings. Radiology, 2002, 225, 451-456.	7.3	161
12	Consensus Expert Recommendations for the Diagnosis and Management of Autosomal Recessive Polycystic Kidney Disease: Report of an International Conference. Journal of Pediatrics, 2014, 165, 611-617.	1.8	138
13	Replication-dependent instability at (CTG)â€¢(CAG) repeat hairpins in human cells. Nature Chemical Biology, 2010, 6, 652-659.	8.0	135
14	Tuberous Sclerosis Complex Renal Disease. Nephron Experimental Nephrology, 2010, 118, e15-e20.	2.2	134
15	Lymphangioleiomyomatosis Screening in Women With Tuberous Sclerosis. Chest, 2013, 144, 578-585.	0.8	129
16	Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study. PLoS ONE, 2017, 12, e0180939.	2.5	128
17	Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Nephrology Dialysis Transplantation, 2016, 31, 111-119.	0.7	120
18	Reduction of postembolization syndrome after ablation of renal angiomyolipoma. American Journal of Kidney Diseases, 2002, 39, 966-971.	1.9	112

#	Article	IF	Citations
19	Apolipoprotein J/Clusterin Prevents a Progressive Glomerulopathy of Aging. Molecular and Cellular Biology, 2002, 22, 1893-1902.	2.3	99
20	Embolization of Renal Angiomyolipomata in Patients With Tuberous Sclerosis Complex. American Journal of Kidney Diseases, 2006, 47, 95-102.	1.9	95
21	Unpaired Structures in SCA10 (ATTCT)nÂ·(AGAAT)n Repeats. Journal of Molecular Biology, 2003, 326, 1095-1111.	4.2	90
22	The human DEK oncogene regulates DNA damage response signaling and repair. Nucleic Acids Research, 2011, 39, 7465-7476.	14.5	82
23	Loss of Primary Cilia Upregulates Renal Hypertrophic Signaling and Promotes Cystogenesis. Journal of the American Society of Nephrology: JASN, 2011, 22, 839-848.	6.1	79
24	The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1. Nephrology Dialysis Transplantation, 2014, 29, 1203-1210.	0.7	79
25	C1 inhibitor hinge region mutations produce dysfunction by different mechanisms. Nature Genetics, 1992, 1, 354-358.	21.4	68
26	Frequency and Imaging Appearance of Hepatic Angiomyolipomas in Pediatric and Adult Patients with Tuberous Sclerosis. American Journal of Roentgenology, 2004, 182, 1027-1030.	2.2	68
27	Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study. Nephron, 2016, 134, 51-58.	1.8	58
28	Infantile Dilated X-Linked Cardiomyopathy, G4.5 Mutations, Altered Lipids, and Ultrastructural Malformations of Mitochondria in Heart, Liver, and Skeletal Muscle. Laboratory Investigation, 2002, 82, 335-344.	3.7	57
29	DNA inverted repeats and human disease. Frontiers in Bioscience - Landmark, 1998, 3, d408-418.	3.0	55
30	Unstable Spinocerebellar Ataxia Type 10 (ATTCT)Â·(AGAAT) Repeats Are Associated with Aberrant Replication at the ATX10 Locus and Replication Origin-Dependent Expansion at an Ectopic Site in Human Cells. Molecular and Cellular Biology, 2007, 27, 7828-7838.	2.3	55
31	Triplex DNA and human disease. Frontiers in Bioscience - Landmark, 2007, 12, 4536.	3.0	53
32	Clinical and Molecular Insights into Tuberous Sclerosis Complex Renal Disease. Pediatric Nephrology, 2011, 26, 839-852.	1.7	51
33	Association between a High-Expressing Interferon-Î³ Allele and a Lower Frequency of Kidney Angiomyolipomas in TSC2 Patients. American Journal of Human Genetics, 2002, 71, 750-758.	6.2	48
34	Glomerulocystic kidney disease. Pediatric Nephrology, 2010, 25, 2049-2059.	1.7	48
35	Renal manifestation of tuberous sclerosis complex. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2018, 178, 338-347.	1.6	48
36	The Tuberous Sclerosis Complex Regulates Trafficking of Glucose Transporters and Glucose Uptake. American Journal of Pathology, 2008, 172, 1748-1756.	3.8	46

#	Article	IF	Citations
37	Alimentary Tract Duplications in Children. Clinical Pediatrics, 1988, 27, 152-157.	0.8	45
38	Evidence for pericyte origin of TSC-associated renal angiomyolipomas and implications for angiotensin receptor inhibition therapy. American Journal of Physiology - Renal Physiology, 2014, 307, F560-F570.	2.7	44
39	Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference. Pediatric Neurology, 2016, 60, 1-12.	2.1	43
40	PKD1 intron 21: triplex DNA formation and effect on replication. Nucleic Acids Research, 2004, 32, 1460-1468.	14.5	41
41	Optimal treatment of tuberous sclerosis complex associated renal angiomyolipomata: a systematic review. Therapeutic Advances in Urology, 2016, 8, 279-290.	2.0	39
42	Acute Kidney Injury in Pediatric Patients Receiving Allogeneic Hematopoietic Cell Transplantation: Incidence, Risk Factors, and Outcomes. Biology of Blood and Marrow Transplantation, 2018, 24, 758-764.	2.0	39
43	Replication Fork Stalling and Checkpoint Activation by a PKD1 Locus Mirror Repeat Polypurine-Polypyrimidine (Pu-Py) Tract. Journal of Biological Chemistry, 2012, 287, 33412-33423.	3.4	38
44	DNA Lesion-specific Co-localization of the Mre11/Rad50/Nbs1 (MRN) Complex and Replication Protein A (RPA) to Repair Foci. Journal of Biological Chemistry, 2005, 280, 12927-12934.	3.4	37
45	The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma. Pediatric Nephrology, 2018, 33, 101-109.	1.7	37
46	Performance of cystatin C-based equations in a pediatric cohort at high risk of kidney injury. Pediatric Nephrology, 2013, 28, 453-461.	1.7	36
47	A step-wise approach for establishing a multidisciplinary team for the management of tuberous sclerosis complex: a Delphi consensus report. Orphanet Journal of Rare Diseases, 2019, 14, 91.	2.7	36
48	Human TSC-associated renal angiomyolipoma cells are hypersensitive to ER stress. American Journal of Physiology - Renal Physiology, 2012, 303, F831-F844.	2.7	33
49	Contiguous deletion and duplication mutations resulting in type 1 hereditary angioneurotic edema. Human Genetics, 1994, 93, 265-269.	3.8	31
50	Automated Algorithm for Quantifying the Extent of Cystic Change on Volumetric Chest CT: Initial Results in Lymphangioleiomyomatosis. American Journal of Roentgenology, 2009, 192, 1037-1044.	2.2	31
51	Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2. Nephrology Dialysis Transplantation, 2019, 34, 1000-1008.	0.7	31
52	Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2. European Journal of Human Genetics, 2015, 23, 1665-1672.	2.8	29
53	Long-term Clinical Morbidity in Patients With Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex. Urology, 2016, 95, 80-87.	1.0	28
54	Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis. PLoS ONE, 2018, 13, e0201005.	2.5	27

#	Article	IF	Citations
55	Comparative evaluation of Î±-galactosidase A infusions for treatment of Fabry disease. Genetics in Medicine, 2003, 5, 144-153.	2.4	25
56	Characterization of Renal Toxicity in Mice Administered the Marine Biotoxin Domoic Acid. Journal of the American Society of Nephrology: JASN, 2014, 25, 1187-1197.	6.1	24
57	A mechanistic approach to inherited polycystic kidney disease. Pediatric Nephrology, 2005, 20, 558-566.	1.7	23
58	Impact of Ultrasound-Guided Kidney Biopsy Simulation on Trainee Confidence and Biopsy Outcomes. American Journal of Nephrology, 2012, 36, 570-574.	3.1	23
59	Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis. British Journal of Clinical Pharmacology, 2016, 81, 958-970.	2.4	23
60	Primary cilia regulate the osmotic stress response of renal epithelial cells through TRPM3. American Journal of Physiology - Renal Physiology, 2017, 312, F791-F805.	2.7	23
61	Tuberous sclerosis complex exhibits a new renal cystogenic mechanism. Physiological Reports, 2019, 7, e13983.	1.7	23
62	Optimizing DpnI Digestion Conditions to Detect Replicated DNA. BioTechniques, 2002, 33, 316-318.	1.8	22
63	Simulation of real-time ultrasound-guided renal biopsy. Kidney International, 2010, 78, 705-707.	5.2	22
64	Analysis of PKD1 for genomic deletion by multiplex ligation-dependent probe assay: Absence of hot spots. Genomics, 2008, 91, 203-208.	2.9	19
65	Increased cancer risk of augmentation cystoplasty: Possible role for hyperosmolal microenvironment on DNA damage recognition. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009, 670, 88-95.	1.0	19
66	Antibody to C1Ì„-inhibitor in a patient receiving C1Ì„-inhibitor infusions for treatment of hereditary angioneurotic edema with systemic lupus erythematosus reacts with a normal allotype of residue 458 of C1Ì„-inhibitor. Translational Research, 1996, 128, 438-443.	2.3	17
67	Tuberous sclerosis complex, mTOR, and the kidney: report of an NIDDK-sponsored workshop. American Journal of Physiology - Renal Physiology, 2014, 306, F279-F283.	2.7	17
68	Hyperglycemia in the absence of cilia accelerates cystogenesis and induces renal damage. American Journal of Physiology - Renal Physiology, 2015, 309, F79-F87.	2.7	16
69	Tuberous Sclerosis Complex Axis Controls Renal Extracellular Vesicle Production and Protein Content. International Journal of Molecular Sciences, 2020, 21, 1729.	4.1	16
70	RecQ and RecG helicases have distinct roles in maintaining the stability of polypurineÂ·polypyrimidine sequences. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2008, 643, 20-28.	1.0	15
71	Rates of interventional procedures in patients with tuberous sclerosis complex-related renal angiomyolipoma. Current Medical Research and Opinion, 2015, 31, 1501-1507.	1.9	15
72	Insight into response to mTOR inhibition when PKD1 and TSC2 are mutated. BMC Medical Genetics, 2015, 16, 39.	2.1	15

#	Article	IF	Citations
73	Rapalog resistance is associated with mesenchymal-type changes in Tsc2-null cells. Scientific Reports, 2019, 9, 3015.	3.3	15
74	Kidney intercalated cells and the transcription factor FOXi1 drive cystogenesis in tuberous sclerosis complex. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	14
75	[6] C1 Inhibitor. Methods in Enzymology, 1993, 223, 97-120.	1.0	13
76	Renal involvement in tuberous sclerosis complex and von Hippelâ€“Lindau disease: shared disease mechanisms?. Nature Reviews Nephrology, 2009, 5, 143-156.	9.6	13
77	Outcomes of angioembolization and nephrectomy for renal angiomyolipoma associated with tuberous sclerosis complex: a real-world US national study. Current Medical Research and Opinion, 2017, 33, 821-827.	1.9	13
78	Replication Protein A is Required for Etoposide-Induced Assembly of MRE11/RAD50/NBS1 Complex Repair Foci. Cell Cycle, 2007, 6, 2408-2416.	2.6	12
79	Congenital Lymphatic Malformation and Aortic Aneurysm in a Patient with TSC2 Mutation. Neuropediatrics, 2020, 51, 057-061.	0.6	12
80	Cell Cycle- and Proteasome-Dependent Formation of Etoposide-Induced Replication Protein A (RPA) or Mre11/Rad50/Nbs1 (MRN) Complex Repair Foci. Cell Cycle, 2007, 6, 2399-2407.	2.6	10
81	Pooled analysis of menstrual irregularities from three major clinical studies evaluating everolimus for the treatment of tuberous sclerosis complex. PLoS ONE, 2017, 12, e0186235.	2.5	10
82	Acute kidney injury in pediatric hematopoietic cell transplantation: critical appraisal and consensus. Pediatric Nephrology, 2022, 37, 1179-1203.	1.7	10
83	C1 Inhibitor Gene Sequence Facilitates Frameshift Mutations. Molecular Medicine, 1998, 4, 795-806.	4.4	9
84	Cell Cycle Control and DNA Damage Response of Conditionally Immortalized Urothelial Cells. PLoS ONE, 2011, 6, e16595.	2.5	9
85	Measurement of glomerular filtration rate by dynamic contrast-enhanced magnetic resonance imaging using a subject-specific two-compartment model. Physiological Reports, 2016, 4, e12755.	1.7	9
86	Tsc2 mutation induces renal tubular cell nonautonomous disease. Genes and Diseases, 2022, 9, 187-200.	3.4	9
87	Nephritic factor and recurrence in the renal transplant of membranoproliferative glomerulonephritis type II. Pediatric Nephrology, 2008, 23, 1867-1876.	1.7	8
88	Natural history of patients with tuberous sclerosis complex related renal angiomyolipoma. Current Medical Research and Opinion, 2017, 33, 1277-1282.	1.9	8
89	Healthcare utilization and costs in patients with tuberous sclerosiscomplex-related renal angiomyolipoma. Journal of Medical Economics, 2017, 20, 388-394.	2.1	7
90	Racial Health Disparity and COVID-19. Journal of NeuroImmune Pharmacology, 2021, 16, 729-742.	4.1	7

#	Article	IF	Citations
91	Paradoxical hypertension in hypovolemic children. Pediatric Emergency Care, 1991, 7, 350-352.	0.9	5
92	Generation, clearance, toxicity, and monitoring possibilities of unaccounted uremic toxins for improved dialysis prescriptions. American Journal of Physiology - Renal Physiology, 2018, 315, F890-F902.	2.7	5
93	Continuous Renal Replacement Therapy: A Review of Use and Application in Pediatric Hematopoietic Stem Cell Transplant Recipients. Frontiers in Oncology, 2021, 11, 632263.	2.8	5
94	Tsc Gene Locus Disruption and Differences in Renal Epithelial Extracellular Vesicles. Frontiers in Physiology, 2021, 12, 630933.	2.8	5
95	Everolimus compliance and persistence among tuberous sclerosis complex patients with renal angiomyolipoma or subependymal giant cell astrocytoma. Current Medical Research and Opinion, 2019, 35, 1103-1110.	1.9	4
96	Renal cystic disease in tuberous sclerosis complex. Experimental Biology and Medicine, 2021, 246, 2111-2117.	2.4	4
97	Renal, hepatic, and marrow dysfunction in a patient with chronic renal insufficiency. Pediatric Nephrology, 2003, 18, 293-296.	1.7	3
98	Cystic Kidney Diseases Associated with Increased Cancer Risk: Tuberous Sclerosis Complex, Von Hippel-Lindau, and Birt-Hogg-DubÃ©. , 2018, , 51-66.		3
99	Single Gene Mutations in Pkd1 or Tsc2 Alter Extracellular Vesicle Production and Trafficking. Biology, 2022, 11, 709.	2.8	3
100	Cutaneous Angiomyolipoma of the Eyelid in a 2-Year-Old With Tuberous Sclerosis Complex. Journal of Neuro-Ophthalmology, 2021, 41, e69-e70.	0.8	2
101	DNA Structures and Genetic Instabilities Associated with Spinocerebellar Ataxia Type 10 (ATTCT) n Â·(AGAAT) n Repeats Suggest a DNA Amplification Model for Repeat Expansion. , 2006, , 447-460.		2
102	Problems of nephrooncology. Proceedings from the 1st Scientific and Training Conference Nephrooncology 5â€“6 October 2018, GdaÅ„sk, Poland. Polish Archives of Internal Medicine, 2019, 129, 1-74.	0.4	2
103	Effect of everolimus on angiogenic biomarkers in patients with tuberous sclerosis complex (TSC): Results from EXIST-1 and EXIST-2.. Journal of Clinical Oncology, 2012, 30, 10619-10619.	1.6	2
104	Therapies for polycystic kidney disease. Current Opinion in Pediatrics, 2015, 27, 227-232.	2.0	1
105	Updated safety results from EXIST-2: Everolimus therapy for angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC) or sporadic lymphangioleiomyomatosis (sLAM).. Journal of Clinical Oncology, 2012, 30, 4632-4632.	1.6	1
106	Leptin receptor defect with diabetes causes skeletal muscle atrophy in female obese Zucker rats where peculiar depots networked with mitochondrial damages. Ultrastructural Pathology, 2021, 45, 346-375.	0.9	1
107	Urinary pCO₂ Monitoring System with a Planar Severinghaus Type Sensor. Electroanalysis, 2022, 34, 1587-1597.	2.9	1
108	Polycystic Kidney Disease. , 2011, , 703-712.		0

#	Article	IF	Citations
109	Intracranial arterial aneurysms in children and young adults. Journal of Pediatric Neuroradiology, 2015, 02, 203-235.	0.1	0
110	Real-world treatment profile for patients with tuberous sclerosis complex related angiomyolipoma: A U.S. Healthcare Claims Database study.. Journal of Clinical Oncology, 2012, 30, e15096-e15096.	1.6	0
111	Prevalence of angiomyolipoma among patients with tuberous sclerosis complex: A U.S. Healthcare Claims Database study.. Journal of Clinical Oncology, 2012, 30, e12042-e12042.	1.6	0
112	Renal function after treatment for childhood cancer.. Journal of Clinical Oncology, 2016, 34, 10571-10571.	1.6	0
113	Tuberous sclerosis complex and the kidney. , 2020, , 251-258.e3.		0
114	Renal Involvement in Tuberous Sclerosis Complex. , 2021, , 1-12.		0